SCHEMBL16227013

SCHEMBL16227013

COc1ccc(O)c2c1C(=O)c1ccc(CO)c(O)c1C2=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.57
▸ PIM1 P11309 1/20 0.57
▸ ELANE P08246 13/20 0.53
▸ MEN1 O00255 5/20 0.51
▸ KMT2A Q03164 5/20 0.51
▸ MAPT P10636 4/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ USP2 O75604 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ HPGD P15428 2/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ RAF1 P04049 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ THRB P10828 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ CSNK2A2 P19784 1/20 0.51
▸ MAOA P21397 1/20 0.51
▸ APEX1 P27695 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16226244 0.82 ELANE (0.76) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL11689685 0.79 EGFR (0.68) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL11299000 0.79 ELANE (0.54) ELANEMEN1KMT2AMAPTKDM4E
SCHEMBL16226288 0.77 EPHX2 (0.54) ELANEMEN1KMT2AMAPTKDM4E
SCHEMBL11297406 0.77 ELANE (0.53) ELANEMEN1KMT2AMAPTKDM4E
SCHEMBL28916427 0.75 KMT2A (0.79) EGFRPIM1MEN1KMT2AMAPT
SCHEMBL11528272 0.73 EGFR (1.00) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL28206847 0.72 MEN1 (0.69) EGFRPIM1ELANEMEN1KMT2A
Digiferruginol SCHEMBL23199057 0.71 ELANE (0.69) ELANEMEN1KMT2AMAPTKDM4E
Digiferruginol SCHEMBL30614617 0.71 ELANE (0.69) ELANEMEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER THE GENERAL HOSPITAL CORPORATION (US) 2014-11-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER IL2RA, CD74, IL2 EGFR 656/4885PIM1 4333/4885ELANE 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback